Skip to main content
. 2022 Nov 8;29(2):389–400. doi: 10.1158/1078-0432.CCR-22-2191

Figure 1.

Figure 1. CONSORT flow diagram for cases included in the GEICAM/CIBOMA translational study cohort of triple-negative breast cancer. The analysis of the translational study cohort followed a prospective–retrospective design testing prespecified primary and secondary hypotheses using high-quality clinical trial materials with adherence to REMARK criteria and to the guidelines for use of archived clinical trial specimens for predictive biomarker evaluation on clinical trials.

CONSORT flow diagram for cases included in the GEICAM/CIBOMA translational study cohort of triple-negative breast cancer. The analysis of the translational study cohort followed a prospective–retrospective design testing prespecified primary and secondary hypotheses using high-quality clinical trial materials with adherence to REMARK criteria and to the guidelines for use of archived clinical trial specimens for predictive biomarker evaluation on clinical trials.